RePORT International Resources

The RePORT International Long TB project will collect data in a variety of ways. 1. A central REDCap build hosted at Frontier Science. All sites must register for accounts to access this central REDCap build to log participant data. 2. The File Exchange Utility (FEU) hosted at Frontier Science. All sites must register for accounts to access this utility to upload de-identified DIACOM scan files. 3. The Data Submission System (DSS) hosted at Frontier Science. All sites must register for accounts to access this utility to upload information about specimen storage and availability. This guide includes instructions for registering for accounts and for accessing and using these tools.

The VALIDATE Network aims to accelerate vaccine research and development for three groups of complex neglected intracellular pathogens that cause significant mortality and morbidity throughout the world, particularly in low-and-middle-income countries (LMICs): Mycobacteria (causing tuberculosis, leprosy and other diseases), Leishmania (causing leishmaniasis) and Burkholderia pseudomallei (causing melioidosis). A second, important aim of the VALIDATE Network is to facilitate career progression for its members, particularly Early Career Researchers (ECRs), and (recognising career progression inequity) researchers from LMICs and researchers identifying as female and/or non-binary. CALL FOR ROUND 6 AWARDS IS EXPECTED IN DECEMBER 2025

This monthly webinar series covers the research and publishing process. Featuring Sage and external speakers from various disciplines, this series addresses the stumbling blocks every researcher encounters at the beginning of their careers and provides practical and in-depth guidance to help get published. For more information and to register for each webinar, click the links below. All webinars occur at 8 am PT/11 am ET/5 pm CET. You can also watch recordings of the previous webinars in the series by scrolling down to our webinar library, where you can find links to all the recordings and topics available at your fingertips anytime, anywhere.

DEADLINE: 26 March, 2026 This scheme provides funding for mid-career researchers from any discipline who have the potential to be international research leaders. They will develop their research capabilities, drive innovative programmes of work and deliver significant shifts in understanding related to human life, health and wellbeing. Please refer to the webiste for the key dates and details.

DEADLINE: 31 March 2026 This scheme provides funding for established researchers and teams from any discipline who want to pursue bold and creative research ideas to deliver significant shifts in understanding related to human life, health and wellbeing. Please refer to the webiste for the key dates and details.

This scheme provides funding for early-career researchers from any discipline who are ready to develop their research identity. Through innovative projects, they will deliver shifts in understanding related to human life, health and wellbeing. By the end of the award, they will be ready to lead their own independent research programme. The applications are opened 3 times a year

DEADLINE: 17 February, 2026 This scheme provides funding for early-career researchers from any discipline who are ready to develop their research identity. Through innovative projects, they will deliver shifts in understanding related to human life, health and wellbeing. By the end of the award, they will be ready to lead their own independent research programme. Please refer to the webiste for the key dates and details.

Wellcome - Grants and Fundings - Searchable Database

This learning platform is custom-built to host high-quality courses developed by the WHO Academy, along with a wide range of quality-approved content from trusted providers. It offers personalized learning pathways, interactive tools, and collaborative features.

This website provides access to the latest WHO recommendations on all aspects of tuberculosis prevention and care. The user can search, filter and cross-tabulate the recommendations through built-in functions. For each individual recommendation one can also access key background information, such as the evidence summaries and the Guideline Development Group decisions underpinning it.

This call to action accompanies the consensus statement on the optimal and early inclusion of pregnant and lactating women in tuberculosis research and specifies the actions that need to be taken to ensure full implementation of the agreed approaches in the statement. The target audience includes product developers and industry, study sponsors, funding agencies, researchers and research networks, regulatory authorities, institutional review boards (IRBs) and ethics committees, national TB and maternal and child health programmes, civil society organizations and affected communities, and health care providers.

This WHO training kit helps manufacturers and regulators, especially in low- and middle-income countries, learn how to produce safe, effective, and high-quality vaccines, medicines, and diagnostic tests. It compiles expert-reviewed Q&As from the “Week of Quality” training on quality standards, regulatory compliance, and product development, serving as a reference for strengthening local production.

The Guidance on evidence generation (GEG) on new regimens for tuberculosis treatment is a first-of-its-kind document that advises researchers, developers, funders, and other stakeholders about how evidence should be generated to optimally inform WHO guideline development on novel regimens for TB treatment. It outlines 21 key messages, explains why they are important, and what approaches can increase the chances of research leading to strong WHO recommendations. The key messages cover areas such as trial design, selection criteria, outcome choice, sample size, analytic and economic considerations, and how to Investigate the impact of an intervention on health equity, acceptability, and feasibility. The evidence available to WHO for use in guideline development has often presented challenges that have limited the strength of recommendations and their applicability to certain population groups or have meant that the evidence is not suitable for policy development. The reasons for these challenges are addressable but are not always well understood by all stakeholders. The guidance provided in the GEG document should allow those who aim to influence policy to design trials and other studies in a way that maximizes the potential to do so.

In 2024, the WHO Global Programme on Tuberculosis & Lung Health led a consensus building process to advance the earlier and optimal inclusion of pregnant women in TB research. The process is aligned with broader global developments to transform clinical trial practices, including addressing the needs of underrepresented populations. This consensus statement summarizes the consensus process, which included five thematic working groups (covering preclinical TB research, TB therapeutics research, TB vaccine research, maternal TB surveillance systems and advocacy), evidence reviews to address gaps in data and knowledge and a consensus meeting in February 2025. The approaches to earlier and optimal inclusion arising from the consensus process include crosscutting actions as well as approaches specific to each working group theme.